1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...

Background More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 ...

Zelenectide pevedotin (BT8009) demonstrated a well-tolerated safety profile and promising antitumor activity in patients with ...

Patients with urinary stones show poorer survival in upper tract urothelial carcinoma. Find out how stone history may affect ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Loqtorzi significantly improved progression-free and overall survival in HER2-expressing advanced urothelial carcinoma compared to chemotherapy. The study demonstrated a higher overall response rate ...

Using the Shiny method, a more nuanced approach to meta-analysis, investigators determined that enfortumab vedotin plus pembrolizumab outperforms chemotherapy-based regimens for urothelial carcinoma.

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes. Among patients with advanced urothelial carcinoma who ...

Patients with low-grade upper tract urothelial carcinoma who achieved a complete response after receiving treatment with ...

Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer. Increases in circulating tumor DNA fraction ...

After a grim diagnosis of Stage IV cancer, a combination of immunotherapy and targeted therapy offered fewer side effects — ...